Assessment of triple antiphospholipid antibody-positive patients based on clinical and laboratory domains of 2023 ACR/EULAR antiphospholipid syndrome classification criteria

Autoimmune Disease

Development of the 2023 ACR/EULAR Antiphospholipid Syndrome Classification Criteria, Phase III-C Report: Assessment of Patient Scenarios (Derivation Cohort) and Refinement of Definitions

Arthritis Care Res (Hoboken)

Barbhaiya M, Zuily S, Jannat-Khah D, Amigo MC, Andrade D, Avcin T, Bertolaccini ML, Branch DW, Costedoat-Chalumeau N, de Jesús GR, Devreese KMJ, Garcia D, Gomez Puerta JA, Guillemin F, Levine SR, Levy RA, Lockshin MD, Ortel TL, Petri M, Sanna G, Sciascia S, Seshan SV, Tektonidou M, Wahl D, Willis R, Yelnik C, Hendry A, Naden R, Costenbader KH, Erkan D, New APS Classification Criteria Collaborators

doi: 10.1002/acr.25599

Autoimmune Disease

Assessing the sensitivity and the clinical impact of the 2023 ACR/EULAR classification criteria in Obstetric Antiphospholid Syndrome: findings from a multicenter Italian cohort with a long-term follow-up

Arthritis Care Res (Hoboken)

Ruffilli F, Nalli C, Crisafulli F, Garaffoni C, Govoni M, Voltarel G, Pozzi AC, Maranini B, Silvagni E, Bortoluzzi A, Tincani A

doi: 10.1002/acr.80040

Rheumatoid Arthritis

Baseline interleukin-10 levels as a predictive biomarker for achieving clinical response with abatacept in disease-modifying antirheumatic drug-naive and anticitrullinated protein antibody-positive patients with early rheumatoid arthritis

Arthritis Rheumatol

Liu J, Li Y, Fu K, Wu C, Schafer P, Connolly SE, Catlett IM, Maldonado MA, Wong R, Emery P, Tanaka Y, Bykerk VP, Bingham CO, Huizinga TWJ, Fleischmann R

doi: 10.1002/art.70106

Systemic Sclerosis

Scleroderma clinical trials consortium classification criteria for systemic sclerosis heart involvement

Rheumatology (Oxford)

Ross L, Burns AT, La Gerche A, Hansen D, Coghlan JG, Stevens W, Prior D, Pham A, McKelvie P, Bellocchi C, Braun Moscovici Y, Bruni C, Carreira P, Frech T, Hoa S, Hudson M, Hsu V, Hsiu Ling Low A, Matucci-Cerinic M, Medina Fonseca B, Ng SA, Rodriguez Reyna T, Sahhar J, Talaat M, Proudman S, Vacca A, Baron M, Nikpour M, SCTC Cardiac Working Group

doi: 10.1093/rheumatology/keag109

Rheumatoid Arthritis

EULAR/ACR risk stratification criteria for development of rheumatoid arthritis in the risk stage of arthralgia

Ann Rheum Dis

van Steenbergen HW, Doornkamp F, Alivernini S, Backlund J, Codreanu C, Cohen SB, Combe B, Cope AP, Deane KD, England BR, Falahee M, de Jong PHP, Kleyer A, Lacaille D, Maat B, Mankia K, van Mulligen E, Nagy G, O'Neil LJ, Rodamaker L, Sahbudin I, van Schaardenburg D, Sepriano A, da Silva JAP, De Smet L, Sparks JA, Steyerberg EW, Studenic P, Wethington E, Landewé RL, Raza K, van der Helm-van Mil AHM

doi: 10.1016/j.ard.2025.01.021

Alopecia Areata

Clinical Characteristics, Subtype Classification and Prognostic Factors of Ophiasis: a Retrospective Study of 150 Patients with Therapeutic Implications

J Am Acad Dermatol

Li F, Zhang W, Wang C, Zhang J, Li X, Zhou C

doi: 10.1016/j.jaad.2026.02.068

Autoimmune Disease

Recurrent thrombosis and hemorrhagic events in a large single-center primary antiphospholipid syndrome cohort: Results from APS-Rio cohort after nearly 1,000 patient-years of follow-up

Semin Arthritis Rheum

Signorelli F, Balbi GGM, Bastos VP, Reis-Carvalho T, Klumb EM, Levy RA

doi: 10.1016/j.semarthrit.2025.152873

Systemic Lupus Erythematosus

Certolizumab pegol to prevent adverse pregnancy outcomes in patients with antiphospholipid syndrome and lupus anticoagulant (IMPACT): results of a prospective, single-arm, open-label, phase 2 trial

Ann Rheum Dis

Branch DW, Kim MY, Guerra MM, Worden J, Laskin CA, DeSancho MT, Landres IV, Knight JS, Slosberg HS, Minett M, Salmon JE

doi: 10.1016/j.ard.2025.02.012

Rheumatoid Arthritis

Cytokine/chemokine profiles in rheumatoid arthritis patients who failed Boolean remission solely due to elevated patient global assessment

Rheumatology (Oxford)

Fukui S, Michitsuji T, Endo Y, Nishino A, Furukawa K, Shimizu T, Umeda M, Sumiyoshi R, Koga T, Iwamoto N, Tamai M, Origuchi T, van Schie KA, Ueki Y, Eiraku N, Yoshitama T, Matsuoka N, Suzuki T, Okada A, Hamada H, Ayano M, Hidaka T, Tsuru T, Huizinga TWJ, Toes REM, Kawakami A, Kawashiri SY

doi: 10.1093/rheumatology/keag020

Related content

Development of the 2023 ACR/EULAR Antiphospholipid Syndrome Classification Criteria, Phase III-C Report: Assessment of Patient Scenarios (Derivation Cohort) and Refinement of Definitions

Assessing the sensitivity and the clinical impact of the 2023 ACR/EULAR classification criteria in Obstetric Antiphospholid Syndrome: findings from a multicenter Italian cohort with a long-term follow-up

Baseline interleukin-10 levels as a predictive biomarker for achieving clinical response with abatacept in disease-modifying antirheumatic drug-naive and anticitrullinated protein antibody-positive patients with early rheumatoid arthritis

Scleroderma clinical trials consortium classification criteria for systemic sclerosis heart involvement

EULAR/ACR risk stratification criteria for development of rheumatoid arthritis in the risk stage of arthralgia

Clinical Characteristics, Subtype Classification and Prognostic Factors of Ophiasis: a Retrospective Study of 150 Patients with Therapeutic Implications

Recurrent thrombosis and hemorrhagic events in a large single-center primary antiphospholipid syndrome cohort: Results from APS-Rio cohort after nearly 1,000 patient-years of follow-up

Certolizumab pegol to prevent adverse pregnancy outcomes in patients with antiphospholipid syndrome and lupus anticoagulant (IMPACT): results of a prospective, single-arm, open-label, phase 2 trial

Cytokine/chemokine profiles in rheumatoid arthritis patients who failed Boolean remission solely due to elevated patient global assessment